Average for any drug is 5 years to peak sales. Daybue sales have actually been remarkable given the GI issues they have contended with, issues that they are clearly starting to get on top of. Still on track to be a blockbuster drug. Clearly there are 'some issues' but they are far from dire, sales continue to grow with some positives indicating growth and retention will likely both trend stronger in the future, and this is still a life changing drug for many families with Rett's and will be for many more that have not yet started.
Ann: Q2 2024 update, page-39
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 582 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 16.36pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable